Skip to main content

Evolent Oncology Program Updates Effective April 1, 2027

Wellcare, and Wellcare With Meridian, in collaboration with Evolent, are implementing updates to the review and administration of oncology services to enhance member and provider experiences. These changes reflect a shared commitment to improving efficiency, reducing administrative burdens, and supporting timely, clinically appropriate care decisions.

What’s Changing

Denial Determinations for Oncology Services

Effective April 1, 2027, Evolent will issue denial determinations for oncology authorization requests that do not meet clinical criteria.

For requests received prior to April 1, 2027, Evolent will continue to issue Recommended Adverse Determinations (RADs) when clinical criteria are not met, and Wellcare will provide the final determination.

Please continue to submit grievances and appeals directly to Wellcare.

Pharmacy Benefit (Part D) Scope Update

Effective April 1, 2027, Evolent’s oncology review scope will be limited to medical-benefit (Part B) medications. All pharmacy-dispensed (Part D) drugs must be submitted directly to Wellcare, in accordance with plan guidelines.

Requests received prior to April 1, 2027 will be administered by Evolent under the current process.

For questions or additional information, please contact Wellcare provider services at 1-855-538-0454 (TTY 711).

Contact Us icon

ᎤᏚᎸᏓ ᎠᏍᏕᎸᏗᎢ? ᎠᎭᏂ ᎣᏤᏙ ᏂᎯ ᏳᏰᎵᏗ.

ᎢᏍᎩᏟᏃᎮᏓ ᏂᎦᏓ
Y0020_WCM_7577750_M / H9916_WCM 178009E_M Last Updated On: 10/1/2026